Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica.
OBJECTIVE
To evaluate PTX3 feasibility to provide a prognostic tool in PMR clinical practice.


METHODS
Circulating PTX3 levels were measured in 93 PMR patients at disease onset and during corticosteroid therapy and in 46 normal controls (NC) by ELISA.


RESULTS
No difference in PTX3 concentrations was observed between NC and PMR either at disease onset and during follow-up or between groups of patients defined according to the presence of recurrence/relapse.


CONCLUSIONS
PTX3 serum levels do not increase significantly in active PMR. Further studies on patients with giant-cell arteritis could evaluate whether large vessel involvement may be associated to increased PTX3 levels.
Pulsatelli
L
L
Istituto Ortopedico Rizzoli, IRCCS, Bologna, Italy. lia.pulsatelli@ior.it.
Peri
G
G
Macchioni
P
P
Boiardi
L
L
Salvarani
C
C
Cantini
F
F
Mantovani
A
A
Meliconi
R
R
D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011111:Polymyalgia Rheumatica / Q000097:blood* / Q000175:diagnosis* / Q000188:drug therapy; D011379:Prognosis; D011446:Prospective Studies; D012008:Recurrence; D000683:Serum Amyloid P-Component / Q000032:analysis*; D000099153:Pentraxins
D015415:Biomarkers; D002097:C-Reactive Protein; D005938:Glucocorticoids; D000683:Serum Amyloid P-Component; D000099153:Pentraxins